Forbes March 26, 2024
The pharmaceutical giant’s new treatment, sotatercept, showed significant benefits for the thousands of patients suffering from pulmonary arterial hypertension in clinical trials.
Nearly 40,000 Americans are known to suffer from pulmonary arterial hypertension (PAH), a disease that causes the blood vessels in their lungs to progressively shrink, increasing both blood pressure and the risk of heart failure. Around 500 to 1,000 new cases are diagnosed every year, with the average patient only surviving about five to seven years after being diagnosed. The vast majority of people with this disease are women, and they are disproportionately Black or Hispanic.
On Tuesday, the Food and Drug Administration approved a new drug to treat this disease called sotatercept which was developed and being...
Today's Sponsors
Today's Sponsor